Gene Therapy R&D Market Report 2025-2035
Description
The Gene Therapy R&D Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Cell and gene therapies (CGTs) are increasingly moving from the research labs to the clinic, owing to the fact that they target particular disease rather than the limited targets of small-molecule therapies. Both methods of therapy aim to introduce healthy cells or correct genetic defects in patients. Cancer is the primary area of interest and nearly half of all cell & gene therapies in clinical trials. CAR-T therapy (Chimeric Antigen Receptors), which combines cell & gene therapy, is one promising cancer treatment. CAR-T therapy takes a patient's immune cells and modifies their DNA to make them respond against cancer cells. The patient's immune system is reintroduced with modified gene cells, allowing immune system to battle the cancer.
The FDA has already given its approval to two CAR-T therapies. When no other treatment options were working, these therapies benefited some cancer patients. With further research activities, these therapies may become more widely available & capable of treating a wider variety of cancers. The registered clinical trials in Q1 2025 were reported to be 2,155 as compared to 2,093 in Q1 2024. Oncology and rare diseases remained the top areas of gene therapy development in both the overall pipeline (preclinical to pre-registration) and in the clinic (Phase I to pre-registration)
Development for rare diseases most commonly occurred in oncology, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development
The recent expansion of U.S. trade tariffs on pharmaceutical and biotechnological imports is expected to increase operational costs for gene therapy developers. As many critical materials, reagents, and specialised instruments used in R&D are sourced internationally, these tariffs could lead to supply chain disruptions, longer lead times, and higher procurement expenses. Smaller research organisations and academic groups may be most affected, as they have limited flexibility to absorb additional costs. Over time, this may encourage greater localisation of production, as companies seek to mitigate exposure to tariff risks by establishing domestic manufacturing and sourcing capabilities. While such measures could strengthen regional resilience, they also risk fragmenting global collaboration networks that have been vital to innovation in gene therapy research and development.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:
The report also includes profiles for some of the leading companies in the Gene Therapy R&D Market, 2025 to 2035, with a focus on this segment of these companies' operations.
Overall world revenue for Gene Therapy R&D Market, 2025 to 2035 in terms of value the market will surpass US$3,500 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 350+ page report provides you with the following knowledge:
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Gene Therapy R&D Market 2025 to 2035, market-leading companies. You will find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
Robust Gene Therapy Pipeline to Boost Growth
Cell and gene therapies (CGTs) are increasingly moving from the research labs to the clinic, owing to the fact that they target particular disease rather than the limited targets of small-molecule therapies. Both methods of therapy aim to introduce healthy cells or correct genetic defects in patients. Cancer is the primary area of interest and nearly half of all cell & gene therapies in clinical trials. CAR-T therapy (Chimeric Antigen Receptors), which combines cell & gene therapy, is one promising cancer treatment. CAR-T therapy takes a patient's immune cells and modifies their DNA to make them respond against cancer cells. The patient's immune system is reintroduced with modified gene cells, allowing immune system to battle the cancer.
The FDA has already given its approval to two CAR-T therapies. When no other treatment options were working, these therapies benefited some cancer patients. With further research activities, these therapies may become more widely available & capable of treating a wider variety of cancers. The registered clinical trials in Q1 2025 were reported to be 2,155 as compared to 2,093 in Q1 2024. Oncology and rare diseases remained the top areas of gene therapy development in both the overall pipeline (preclinical to pre-registration) and in the clinic (Phase I to pre-registration)
Development for rare diseases most commonly occurred in oncology, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development
What would be the Impact of US Trade Tariffs on the Global Gene Therapy R&D Market?
The recent expansion of U.S. trade tariffs on pharmaceutical and biotechnological imports is expected to increase operational costs for gene therapy developers. As many critical materials, reagents, and specialised instruments used in R&D are sourced internationally, these tariffs could lead to supply chain disruptions, longer lead times, and higher procurement expenses. Smaller research organisations and academic groups may be most affected, as they have limited flexibility to absorb additional costs. Over time, this may encourage greater localisation of production, as companies seek to mitigate exposure to tariff risks by establishing domestic manufacturing and sourcing capabilities. While such measures could strengthen regional resilience, they also risk fragmenting global collaboration networks that have been vital to innovation in gene therapy research and development.
What Questions Should You Ask before Buying a Market Research Report?
- How is the gene therapy R&D market evolving?
- What is driving and restraining the gene therapy R&D market?
- How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
- How will the market shares for each gene therapy R&D submarket develop from 2025 to 2035?
- What will be the main driver for the overall market from 2025 to 2035?
- Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
- Who are the leading players and what are their prospects over the forecast period?
- What are the gene therapy R&D projects for these leading companies?
- How will the industry evolve during the period between 2025 and 2035? What are the implications of
gene therapy R&D projects taking place now and over the next 10 years? - Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
- Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Gene Therapy R&D market today, and over the next 10 years:
- Our 357-page report provides 155 tables and 185 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2035 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.
Segments Covered in the Report
Disease
- Cancer
- Rare Diseases
- Cardiovascular Diseases
- Ophthalmic Diseases
- Haematology
- Neurological
- Diabetes Mellitus
- Other Diseases
Vector
- Viral
- Retrovirus
- Adenovirus
- AAV
- Lentivirus
- Others - Non-viral
- Naked DNA
- Gene Gun
- Electroporation
- Lipofection
Techniques
- Gene Augmentation Therapy
- Gene Replacement Therapy
Participants
- Small/Medium Pharma & Biotech
- Universities & Research Institutes
- Hospitals, Government & Public Bodies
- Big Pharma
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles for some of the leading companies in the Gene Therapy R&D Market, 2025 to 2035, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth
- American Gene Technologies
- Applied Genetic
- Astellas Pharma Inc.
- Bayer
- Benitec BioPharma
- Biogen
- Bluebird Bio
- Bristol Myers Squibb
- Calimmune, Inc. (CSL Behiring)
- Cellectis
- GenSight Biologics
- Gilead Lifesciences, Inc.
- GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.)
- Novartis AG
- OCUGEN, INC.
- Orchard Therapeutics
- Oxford Biomedica
- Pfizer, Inc.
- REGENXBIO Inc.
- Sangamo Therapeutics, Inc.
- Sanofi
- Sarepta Therapeutics, Inc.
- Spark Therapeutics (Subsidiary of Roche)
- Takeda Pharmaceutical Company Limited
- Taysha GTx
- Transgene
- UniQure N. V.
- VeonGen Therapeutics
- Voyager Therapeutics Inc.
Overall world revenue for Gene Therapy R&D Market, 2025 to 2035 in terms of value the market will surpass US$3,500 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Gene Therapy R&D Market, 2025 to 2035 report help you?
In summary, our 350+ page report provides you with the following knowledge:
- Revenue forecasts to 2035 for Gene Therapy R&D Market 2025 to 2035, with forecasts for Disease, Vector, Techniques, and Participants, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2035 for five regional and 22 key national markets - See forecasts for the Gene Therapy R&D Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 29 of the major companies involved in the Gene Therapy R&D Market, 2025 to 2035.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Gene Therapy R&D Market 2025 to 2035, market-leading companies. You will find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
Table of Contents
357 Pages
- 1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Gene Therapy R&D Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report Include:
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2 Executive Summary
- 3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Robust Gene Therapy Pipeline to Boost Growth
- 3.2.1.2 Technological Advancements to Fuel Market Growth
- 3.2.1.3 Role of Artificial Intelligence and Machine Learning in Gene Therapy
- 3.2.1.4 Increasing Financing and Acquisitions by Major Players
- 3.2.1.5 Growing Prevalence of Targeted Diseases Treatment
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Cell & Gene Therapies Target Specific Diseases
- 3.2.2.2 High Cost to Stifle Gene Therapy R&D Growth
- 3.2.2.3 Regulatory Scenarios to Challenge Industry Growth
- 3.2.3 Market Opportunities
- 3.2.3.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
- 3.2.3.2 Expansion of Clinical Trials and CAR-T Therapies
- 3.2.3.3 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
- 3.2.3.4 Artificial Intelligence Can Bring Value to Gene Therapy R&D
- 3.1 U.S. Tariffs: What's the Impact on Global Gene Therapy R&D Market?
- 3.1.1 Overview
- 3.1.2 V-Shaped Recovery Scenario
- 3.1.3 Why V-Shaped Recovery?
- 3.1.3.1 Impact from Tariffs
- 3.1.3.2 Market Dynamics and Demand Recovery
- 3.1.3.3 Policy and Funding Support
- 3.1.3.4 Timeframe for Recovery
- 3.1.4 U-Shaped Recovery Scenario
- 3.1.4.1 Why U-Shaped Recovery?
- 3.1.4.2 Impact from Tariffs
- 3.1.4.3 Market Dynamics and Demand Recovery
- 3.1.4.4 Policy and Funding Support
- 3.1.4.5 Timeframe for Recovery
- 3.1.5 L Shaped Recovery Scenario
- 3.1.5.1 Why L-Shaped Recovery?
- 3.1.5.2 Impact from Tariffs
- 3.1.5.3 Market Dynamics and Demand Recovery
- 3.1.5.4 Policy and Funding Support
- 3.1.5.5 Timeframe for Recovery
- 3.1.6 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
- 3.1.7 Impact of U.S. and China Trade War on Gene Therapy R&D Market
- 3.1.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
- 3.2 Porter's Five Forces Analysis
- 3.2.1 Bargaining Power of Suppliers
- 3.2.2 Bargaining Power of Buyers
- 3.2.3 Competitive Rivalry
- 3.2.4 Threat of Substitute Products
- 3.2.5 Threat of New Entrants
- 3.3 PEST Analysis
- 3.3.1 Political Factors Impacting Gene Therapy R&D Market
- 3.3.2 Economic Factors Impacting Gene Therapy R&D Market
- 3.3.3 Social Factors Impacting Gene Therapy R&D Market
- 3.3.4 Technological Factors Impacting Gene Therapy R&D Market
- 4 Gene Therapy R&D Market Analysis by Disease
- 4.1 Key Findings
- 4.2 Disease Segment: Market Attractiveness Index
- 4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 4.4 Cancer
- 4.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.4.2 Market Share by Region, 2025 & 2035 (%)
- 4.5 Rare Diseases
- 4.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.5.2 Market Share by Region, 2025 & 2035 (%)
- 4.5.3 Rare Diseases Market Size Estimation and Forecast by Type
- 4.5.3.1 Oncologic
- 4.5.3.2 Non-oncologic
- 4.6 Cardiovascular Diseases
- 4.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.6.2 Market Share by Region, 2025 & 2035 (%)
- 4.7 Ophthalmic Diseases
- 4.7.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.7.2 Market Share by Region, 2025 & 2035 (%)
- 4.8 Haematology
- 4.8.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.8.2 Market Share by Region, 2025 & 2035 (%)
- 4.9 Neurological
- 4.9.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.9.2 Market Share by Region, 2025 & 2035 (%)
- 4.10 Diabetes Mellitus
- 4.10.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.10.2 Market Share by Region, 2025 & 2035 (%)
- 4.11 Other Diseases
- 4.11.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 4.11.2 Market Share by Region, 2025 & 2035 (%)
- 5 Gene Therapy R&D Market Analysis by Vector
- 5.1 Key Findings
- 5.2 Vector Segment: Market Attractiveness Index
- 5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 5.4 Viral
- 5.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 5.4.2 Market Share by Region, 2025 & 2035 (%)
- 5.4.3 Viral Vector Market Size Estimation and Forecast by Type
- 5.4.3.1 Retrovirus
- 5.4.3.2 Adenovirus
- 5.4.3.3 AAV
- 5.4.3.4 Lentivirus
- 5.4.3.5 Others
- 5.5 Non-viral
- 5.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 5.5.2 Market Share by Region, 2025 & 2035 (%)
- 5.5.3 Non-viral Vector Market Size Estimation and Forecast by Type
- 5.5.3.1 Naked DNA
- 5.5.3.2 Gene Gun
- 5.5.3.3 Electroporation
- 5.5.3.4 Lipofection
- 6 Gene Therapy R&D Market Analysis by Techniques
- 6.1 Key Findings
- 6.2 Techniques Segment: Market Attractiveness Index
- 6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 6.4 Gene Augmentation Therapy
- 6.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 6.4.2 Market Share by Region, 2025 & 2035 (%)
- 6.5 Gene Replacement Therapy
- 6.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 6.5.2 Market Share by Region, 2025 & 2035 (%)
- 7 Gene Therapy R&D Market Analysis by Participants
- 7.1 Key Findings
- 7.2 Participants Segment: Market Attractiveness Index
- 7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 7.4 Small/Medium Pharma & Biotech
- 7.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 7.4.2 Market Share by Region, 2025 & 2035 (%)
- 7.5 Universities & Research Institutes
- 7.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 7.5.2 Market Share by Region, 2025 & 2035 (%)
- 7.6 Hospitals, Government & Public Bodies
- 7.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 7.6.2 Market Share by Region, 2025 & 2035 (%)
- 7.7 Big Pharma
- 7.7.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
- 7.7.2 Market Share by Region, 2025 & 2035 (%)
- 8 Gene Therapy R&D Market Analysis by Region
- 8.1 Key Findings
- 8.2 Regional Market Size Estimation and Forecast
- 9 North America Gene Therapy R&D Market Analysis
- 9.1 Key Findings
- 9.2 North America Gene Therapy R&D Market Attractiveness Index
- 9.3 North America Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
- 9.4 North America Gene Therapy R&D Market Size Estimation and Forecast by Country
- 9.5 North America Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 9.6 North America Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 9.7 North America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 9.8 North America Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 9.9 U.S. Gene Therapy R&D Market Analysis
- 9.10 Canada Gene Therapy R&D Market Analysis
- 10 Europe Gene Therapy R&D Market Analysis
- 10.1 Key Findings
- 10.2 Europe Gene Therapy R&D Market Attractiveness Index
- 10.3 Europe Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
- 10.4 Europe Gene Therapy R&D Market Size Estimation and Forecast by Country
- 10.5 Europe Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 10.6 Europe Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 10.7 Europe Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 10.8 Europe Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 10.9 Germany Gene Therapy R&D Market Analysis
- 10.10 UK Gene Therapy R&D Market Analysis
- 10.11 France Gene Therapy R&D Market Analysis
- 10.12 Italy Gene Therapy R&D Market Analysis
- 10.13 Spain Gene Therapy R&D Market Analysis
- 10.14 Russia Gene Therapy R&D Market Analysis
- 10.15 Rest of Europe Gene Therapy R&D Market Analysis
- 11 Asia Pacific Gene Therapy R&D Market Analysis
- 11.1 Key Findings
- 11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
- 11.3 Asia Pacific Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
- 11.4 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Country
- 11.5 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 11.6 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 11.7 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 11.8 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 11.9 Japan Gene Therapy R&D Market Analysis
- 11.10 China Gene Therapy R&D Market Analysis
- 11.11 India Gene Therapy R&D Market Analysis
- 11.12 Australia Gene Therapy R&D Market Analysis
- 11.13 South Korea Gene Therapy R&D Market Analysis
- 11.14 South East Asia Gene Therapy R&D Market Analysis
- 11.15 Rest of Asia Pacific Gene Therapy R&D Market Analysis
- 12 Latin America Gene Therapy R&D Market Analysis
- 12.1 Key Findings
- 12.2 Latin America Gene Therapy R&D Market Attractiveness Index
- 12.3 Latin America Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
- 12.4 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Country
- 12.5 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 12.6 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 12.7 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 12.8 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 12.9 Brazil Gene Therapy R&D Market Analysis
- 12.10 Mexico Gene Therapy R&D Market Analysis
- 12.11 Rest of Latin America Gene Therapy R&D Market Analysis
- 13 MEA Gene Therapy R&D Market Analysis
- 13.1 Key Findings
- 13.2 MEA Gene Therapy R&D Market Attractiveness Index
- 13.3 MEA Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
- 13.4 MEA Gene Therapy R&D Market Size Estimation and Forecast by Country
- 13.5 MEA Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 13.6 MEA Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 13.7 MEA Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 13.8 MEA Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 13.9 GCC Gene Therapy R&D Market Analysis
- 13.10 South Africa Gene Therapy R&D Market Analysis
- 13.11 Rest of MEA Gene Therapy R&D Market Analysis
- 14 Company Profiles
- 14.1 Astellas Pharma Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Company Overview
- 14.1.3 Financial Analysis
- 14.1.3.1 Net Revenue, 2015-2024
- 14.1.3.2 R&D, 2020-2024
- 14.1.4 Product Benchmarking
- 14.2 American Gene Technologies
- 14.2.1 Company Snapshot
- 14.2.2 Company Overview
- 14.2.3 Product Benchmarking
- 14.3 Beacon Therapeutics
- 14.3.1 Company Snapshot
- 14.3.2 Company Overview
- 14.3.3 Product Benchmarking
- 14.3.4 Strategic Outlook
- 14.4 Bayer
- 14.4.1 Company Snapshot
- 14.4.2 Company Overview
- 14.4.3 Financial Analysis
- 14.4.3.1 Net Revenue, 2020-2024
- 14.4.3.2 R&D, 2020-2024
- 14.4.4 Product Benchmarking
- 14.4.5 Strategic Outlook
- 14.5 Benitec BioPharma
- 14.5.1 Company Snapshot
- 14.5.2 Company Overview
- 14.5.3 Product Benchmarking
- 14.6 Biogen
- 14.6.1 Company Snapshot
- 14.6.2 Company Overview
- 14.6.3 Financial Analysis
- 14.6.3.1 Net Revenue, 2020-2024
- 14.6.3.2 Regional Market Shares, 2024
- 14.6.3.3 R&D, 2020-2024
- 14.6.4 Product Benchmarking
- 14.6.5 Strategic Outlook
- 14.7 Bluebird Bio
- 14.7.1 Company Snapshot
- 14.7.2 Company Overview
- 14.7.3 Financial Analysis
- 14.7.3.1 Net Revenue, 2020-2024
- 14.7.3.2 R&D, 2020-2024
- 14.7.4 Product Benchmarking
- 14.7.5 Strategic Outlook
- 14.8 Bristol Myers Squibb
- 14.8.1 Company Snapshot
- 14.8.2 Company Overview
- 14.8.3 Financial Analysis
- 14.8.3.1 Net Revenue, 2020-2024
- 14.8.3.2 Regional Market Shares, 2024
- 14.8.3.3 R&D, 2020-2024
- 14.8.4 Product Benchmarking
- 14.8.5 Strategic Outlook
- 14.9 Calimmune, Inc. (CSL Behiring)
- 14.9.1 Company Snapshot
- 14.9.2 Company Overview
- 14.9.3 Product Benchmarking
- 14.9.4 Strategic Outlook
- 14.10 Cellectis
- 14.10.1 Company Snapshot
- 14.10.2 Company Overview
- 14.10.3 Financial Analysis
- 14.10.3.1 Net Revenue, 2020-2024
- 14.10.3.2 R&D, 2020-2024
- 14.10.4 Product Benchmarking
- 14.11 GenSight Biologics
- 14.11.1 Company Snapshot
- 14.11.2 Company Overview
- 14.11.3 Product Benchmarking
- 14.12 Gilead Lifesciences, Inc.
- 14.12.1 Company Snapshot
- 14.12.2 Company Overview
- 14.12.3 Financial Analysis
- 14.12.3.1 Net Revenue, 2020-2024
- 14.12.3.2 R&D, 2020-2024
- 14.12.4 Product Benchmarking
- 14.13 Novartis AG
- 14.13.1 Company Snapshot
- 14.13.2 Company Overview
- 14.13.3 Financial Analysis
- 14.13.3.1 Net Revenue, 2020-2024
- 14.13.3.2 Regional Market Shares, 2024
- 14.13.3.3 R&D, 2020-2024
- 14.13.4 Product Benchmarking
- 14.13.5 Strategic Outlook
- 14.14 Orchard Therapeutics
- 14.14.1 Company Snapshot
- 14.14.2 Company Overview
- 14.14.3 Product Benchmarking
- 14.15 Oxford Biomedica
- 14.15.1 Company Snapshot
- 14.15.2 Company Overview
- 14.15.3 Financial Analysis
- 14.15.3.1 Net Revenue, 2020-2024
- 14.15.3.2 R&D, 2020-2024
- 14.15.4 Product Benchmarking
- 14.15.5 Strategic Outlook
- 14.16 Pfizer, Inc.
- 14.16.1 Company Snapshot
- 14.16.2 Company Overview
- 14.16.3 Financial Analysis
- 14.16.3.1 Net Revenue, 2020-2024
- 14.16.3.2 Regional Market Shares, 2024
- 14.16.3.3 R&D, 2020-2024
- 14.16.4 Product Benchmarking
- 14.16.5 Strategic Outlook
- 14.17 REGENXBIO Inc.
- 14.17.1 Company Snapshot
- 14.17.2 Company Overview
- 14.17.3 Financial Analysis
- 14.17.3.1 Net Revenue, 2020-2024
- 14.17.3.2 R&D, 2020-2024
- 14.17.4 Product Benchmarking
- 14.17.5 Strategic Outlook
- 14.18 Sangamo Therapeutics, Inc.
- 14.18.1 Company Snapshot
- 14.18.2 Company Overview
- 14.18.3 Financial Analysis
- 14.18.3.1 Net Revenue, 2020-2024
- 14.18.3.2 R&D, 2020-2024
- 14.18.4 Product Benchmarking
- 14.18.5 Strategic Outlook
- 14.19 Sanofi
- 14.19.1 Company Snapshot
- 14.19.2 Company Overview
- 14.19.3 Financial Analysis
- 14.19.3.1 Net Revenue, 2020-2024
- 14.19.3.2 Regional Market Shares, 2024
- 14.19.3.3 R&D, 2020-2024
- 14.19.4 Product Benchmarking
- 14.19.5 Strategic Outlook
- 14.20 Spark Therapeutics (Subsidiary of Roche)
- 14.20.1 Company Snapshot
- 14.20.2 Company Overview
- 14.20.3 Product Benchmarking
- 14.21 Takeda Pharmaceutical Company Limited
- 14.21.1 Company Snapshot
- 14.21.2 Company Overview
- 14.21.3 Financial Analysis
- 14.21.3.1 Net Revenue, 2020-2024
- 14.21.3.2 R&D, 2020-2024
- 14.21.4 Product Benchmarking
- 14.22 Transgene
- 14.22.1 Company Snapshot
- 14.22.2 Company Overview
- 14.22.3 Product Benchmarking
- 14.23 UniQure NV
- 14.23.1 Company Snapshot
- 14.23.2 Company Overview
- 14.23.3 Financial Analysis
- 14.23.3.1 Net Revenue, 2020-2024
- 14.23.3.2 R&D, 2020-2024
- 14.23.4 Product Benchmarking
- 14.23.5 Strategic Outlook
- 14.24 Voyager Therapeutics Inc.
- 14.24.1 Company Snapshot
- 14.24.2 Company Overview
- 14.24.3 Financial Analysis
- 14.24.3.1 Net Revenue, 2020-2024
- 14.24.3.2 R&D, 2020-2024
- 14.24.4 Product Benchmarking
- 14.24.5 Strategic Outlook
- 14.25 VeonGen Therapeutics
- 14.25.1 Company Snapshot
- 14.25.2 Company Overview
- 14.25.3 Product Benchmarking
- 14.25.4 Strategic Outlook
- 14.26 GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.)
- 14.26.1 Company Snapshot
- 14.26.2 Company Overview
- 14.26.3 Product Benchmarking
- 14.26.4 Strategic Outlook
- 14.27 OCUGEN, INC.
- 14.27.1 Company Snapshot
- 14.27.2 Company Overview
- 14.27.3 Product Benchmarking
- 14.27.4 Strategic Outlook
- 14.28 Taysha GTx
- 14.28.1 Company Snapshot
- 14.28.2 Company Overview
- 14.28.3 Product Benchmarking
- 14.29 Sarepta Therapeutics, Inc.
- 14.29.1 Company Snapshot
- 14.29.2 Company Overview
- 14.29.3 Product Benchmarking
- 14.29.4 Strategic Outlook
- 15 Conclusion and Recommendations
- 15.1 Concluding Remarks from Visiongain
- 15.2 Recommendations for Market Players
- List of Other Companies Mentioned in the Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
